These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 8333073

  • 1. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA.
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [Abstract] [Full Text] [Related]

  • 2. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 4. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 5. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC, Powderly WG, Storch GA, Miller SB, Dunkel JD, Woodward RS, Spitznagel E, Hanto DW, Dunagan WC.
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [Abstract] [Full Text] [Related]

  • 6. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 7. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S, Zafar MN, Best J, Reddy HK.
    J Cardiovasc Pharmacol Ther; 2006 Mar 27; 11(1):77-83. PubMed ID: 16703222
    [Abstract] [Full Text] [Related]

  • 8. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K, Ranganathan S, Mazariegos G, Bond G, Soltys K, Ganoza A, Sun Q, Sindhi R.
    Pediatr Transplant; 2020 Aug 27; 24(5):e13723. PubMed ID: 32424963
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
    Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL.
    J Infect Dis; 1992 Nov 27; 166(5):986-94. PubMed ID: 1328412
    [Abstract] [Full Text] [Related]

  • 11. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.
    Transplantation; 2003 Nov 15; 76(9):1289-93. PubMed ID: 14627905
    [Abstract] [Full Text] [Related]

  • 12. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA, Andersen HK, Hamilton-Dutoit SJ.
    Transplantation; 1999 May 15; 67(9):1209-14. PubMed ID: 10342310
    [Abstract] [Full Text] [Related]

  • 13. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 14. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun 15; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 15. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Jun 15; 38(6):1755-8. PubMed ID: 16908272
    [Abstract] [Full Text] [Related]

  • 16. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N.
    Clin Transplant; 2016 Jan 15; 30(1):60-5. PubMed ID: 26497471
    [Abstract] [Full Text] [Related]

  • 17. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A, Jiménez L, Aranda I, Alvarez L, González M, Rocamora N, Olivares J.
    Nefrologia; 2002 Jan 15; 22(5):463-9. PubMed ID: 12497748
    [Abstract] [Full Text] [Related]

  • 18. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T, Zwick DL, Rothberg PG, Warady BA.
    Pediatr Nephrol; 1999 Nov 15; 13(9):748-54. PubMed ID: 10603113
    [Abstract] [Full Text] [Related]

  • 19. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 20. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B, Riella LV, Dierickx D.
    Am J Kidney Dis; 2021 Aug 27; 78(2):272-281. PubMed ID: 33774079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.